Pfizer Prevnar vaccine wins approval for ages 6-17

Sat Jan 26, 2013 3:41am IST

Related Topics

Stocks

   

(Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.

The product was already approved in the United States to prevent infections among children aged 6 weeks through 5 years. It is also approved for adults aged 50 and older.

The vaccine protects against infection with 13 strains of the Streptococcus pneumoniae bacterium. The bacterium can cause pneumonia, ear infections and other problems.

Prevnar 13 has annual sales of about $3.5 billion, making it Pfizer's third-biggest brand. It was approved in 2010, and has largely displaced an older vaccine called Prevnar, which protected against only 7 prevalent strains of the bacterium.

(Reporting by Ransdell Pierson; Editing by David Gregorio and Dan Grebler)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Interview

REUTERS SHOWCASE

No Relief

No Relief

Paracetamol no better than placebo for low back pain, study finds.  Full Article 

Fighting AIDS

Fighting AIDS

Bill Clinton says AIDS-free generation 'within reach'.  Full Article 

Obamacare Enrollment

Obamacare Enrollment

Over 10 million U.S. adults gain coverage under Obamacare: study.  Full Article 

Quality Issue

Quality Issue

Ipca halts U.S. shipments from Ratlam plant after FDA finds violations.  Full Article 

Financial Cost

Financial Cost

Abuse of U.S. generic-drug rules costs billions: report.  Full Article 

Fitness Hooping

Fitness Hooping

Hoopsters put circus-inspired spin on cardio workout.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage